m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG00760)
Name
N,N'-Bis-(4-ethyl-phenyl)-guanidine
Synonyms
CHEMBL78083; Guanidine, N,N'-bis(4-ethylphenyl)-; 128413-47-8; ACMC-20msu7; SCHEMBL6155127; SCHEMBL10825147; CTK0C1708; DTXSID70563854; 1,3-Bis(4-ethylphenyl)guanidine; N,N''-Bis(4-ethylphenyl)guanidine; BDBM50010736; ZINC13733770; AKOS030602502
    Click to Show/Hide
Status
Investigative
Structure
Formula
C17H21N3
InChI
1S/C17H21N3/c1-3-13-5-9-15(10-6-13)19-17(18)20-16-11-7-14(4-2)8-12-16/h5-12H,3-4H2,1-2H3,(H3,18,19,20)
InChIKey
DXGARAMIKHFTJV-UHFFFAOYSA-N
PubChem CID
14771671
TTD Drug ID
D04JJL
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Glutamate receptor ionotropic NMDA 1 (NMDAR1)
Fat mass and obesity-associated protein (FTO)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Glutamate receptor ionotropic NMDA 1 (NMDAR1) is a therapeutic target for N,N'-Bis-(4-ethyl-phenyl)-guanidine. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of N,N'-Bis-(4-ethyl-phenyl)-guanidine through regulating the expression of Glutamate receptor ionotropic NMDA 1 (NMDAR1). [1], [2]
References
Ref 1 Down-Regulation of m6A mRNA Methylation Is Involved in Dopaminergic Neuronal Death. ACS Chem Neurosci. 2019 May 15;10(5):2355-2363. doi: 10.1021/acschemneuro.8b00657. Epub 2019 Mar 14.
Ref 2 Synthesis and pharmacological evaluation of N,N'-diarylguanidines as potent sodium channel blockers and anticonvulsant agents. J Med Chem. 1998 Aug 13;41(17):3298-302. doi: 10.1021/jm980134b.